posted 6 days ago
BioMarin Pharmaceutical Inc. Careers - Senior Director, Health Economics & Outcomes Research (HEOR)
Active
Job description
Careers Home Our Story Working Here Career Areas Locations { "@context": "http://schema.org", "@type": "JobPosting", "datePosted": "2026-08-18", "description": "
Who We Are
BioMarin is a leading rare disease biotechnology company focused on genetically defined conditions.
Guided by our purpose to develop medicines that make a profound impact on people\u2019s lives, our global teams have delivered a portfolio of therapies since our founding in 1997. Our revolutionary treatments for conditions like achondroplasia (the most common form of dwarfism), PKU (phenylketonuria), CLN2, a form of Batten disease, and a number of forms of MPS (mucopolysaccharidosis) offer new possibilities for patients and families who previously had few, if any, available options. More recently, with the close of the Amicus acquisition, our portfolio has expanded to include therapies for Fabry disease and Pompe disease, expanding our ability to reach more people living with rare genetic conditions.
Our success comes from our unwavering commitment to excellence, our deep understanding of patient needs, our scientific expertise, and our world-class manufacturing capabilities. At the heart of BioMarin is a dedicated team of the brightest minds in the industry working together to deliver innovative therapies to patients and families around the world.
About Commercial
Be part of the worldwide infrastructure that gets our drugs to underserved patients around the world. Our global sales force solidifies BioMarin\u2019s commercial presence in the United States and Europe and is rapidly growing in other regions, such as South America, EuMEA, and Asia-Pacific.
Who We Are
BioMarin is a leading rare disease biotechnology company focused on genetically defined conditions.
Guided by our purpose to develop medicines that make a profound impact on people\u2019s lives, our global teams have delivered a portfolio of therapies since our founding in 1997. Our revolutionary treatments for conditions like achondroplasia (the most common form of dwarfism), PKU (phenylketonuria), CLN2, a form of Batten disease, and a number of forms of MPS (mucopolysaccharidosis) offer new possibilities for patients and families who previously had few, if any, available options. More recently, with the close of the Amicus acquisition, our portfolio has expanded to include therapies for Fabry disease and Pompe disease, expanding our ability to reach more people living with rare genetic conditions.
Our success comes from our unwavering commitment to excellence, our deep understanding of patient needs, our scientific expertise, and our world-class manufacturing capabilities. At the heart of BioMarin is a dedicated team of the brightest minds in the industry working together to deliver innovative therapies to patients and families around the world.
\u00A0
Senior Director, Health Economics and Outcomes Research
Location: London ( hybrid role 2-3 days per week onsite)
Closing date: 31 August 2026
\u00A0
Summary
The Health Economics & Outcomes Research (HEOR) Senior Director leads asset-specific payer evidence strategies, including patient-relevant outcomes strategy, to generate differentiated evidence, strengthen the payer value proposition, and optimize access for BioMarin assets across all therapeutic areas of interest. s. The role is responsible for shaping patient-relevant outcomes requirements within the clinical programs, ensuring alignment with Regulatory, HTA and access needs. In partnership with internal cross-functional and external stakeholders, the Senior Director leads the design and execution of patient-relevant outcomes research initiatives.
The Sr. Director cultivates strong partnerships with cross-functional partners across Value & Access, Commercial, Medical Affairs, Clinical Development, Regulatory Affairs and Patient Advocacy, while engaging with external stakeholders including HTA agencies, payers and patient organizations. This role requires deep expertise in patient-relevant outcomes research and a strong understanding of market access, value and HTA frameworks.
The position reports to the ED, Head of the Global HEOR team, which sits within the Pricing Access Value & Evidence (PAVE) organization and has a direct report.
\u00A0
Description
\u2022 \u00A0 \u00A0Lead the development, execution and communication of payer evidence strategies aligned with brand and Value & Access priorities for early-stage pipeline assets
\u2022 \u00A0 \u00A0Collaborate closely with Value & Access, Commercial, Medical Affairs, Clinical Development & Regulatory Affairs & Patient Advocacy organizations
\u2022 \u00A0 \u00A0Drive organizational understanding of payer and HTA requirements related to patient-relevant outcomes and health utility measurement
\u2022 \u00A0 \u00A0Drive the strategic assessment for patient-relevant outcomes requirements for HTA and access to support differentiation and value demonstration
\u2022 \u00A0 \u00A0Ensure payer evidence requirements are incorporated into clinical development plans to enable optimal patient access
\u2022 \u00A0 \u00A0Lead the development of cross-functionally aligned, asset-specific patient-relevant outcomes strategies informed by disease conceptual models
\u2022 \u00A0 \u00A0Lead patient-relevant endpoint planning and provide oversight of implementation within clinical trials
\u2022 \u00A0 \u00A0Lead early Joint Clinical Assessment (JCA) strategy development, including assessment of access implications and trade-offs across markets
\u2022 \u00A0 \u00A0Assess payer evidence gaps and inform future integrated evidence planning for early-stage pipeline assets
\u2022 \u00A0 \u00A0Manage and partner with external partners in the execution of asset-level patient-relevant outcomes strategies, including PRO development and validation, health state valuation studies (time trade-off or standard gamble), and patient preference research, as appropriate
\u2022 \u00A0 \u00A0Lead scientific interactions with HTA agencies, particularly scientific advice (e.g., EU HTA JSC, NICE, CADTH), including preparation of briefing materials and evidence packages related to PRO endpoints, MCIDs, etc
\u2022 \u00A0 \u00A0Support scientific interactions with regulatory agencies and patient advocacy organizations
\u2022 \u00A0 \u00A0In partnership with the Integrated Evidence Teams (IET), lead the exploration, analysis and interpretation of patient-relevant outcomes data from clinical trials to generate insights, and strengthen value propositions for HTA, payer and other stakeholders
\u2022 \u00A0 \u00A0Shape strategic scientific communication plans, and lead presentation and publication of research in peer-reviewed journals
\u2022 \u00A0 \u00A0Assess business development opportunities against payer and HTA requirements to identify risks, evidence gaps, and access considerations
\u00A0
Education & Experience
\u2022 \u00A0 \u00A012+ years of Pharma Industry experience with 7+ years of experience in HEOR roles in pharmaceutical companies or consulting, and at least 5 years of direct experience with patient-relevant outcomes research
\u2022 \u00A0 \u00A0Advanced degree in health economics, outcomes research, epidemiology, public health, health services research, pharmacy, or a related scientific discipline
\u2022 \u00A0 \u00A0Deep understanding of market access, value and global HTA frameworks
\u2022 \u00A0 \u00A0Demonstrated experience developing and executing patient-relevant outcomes strategies to meet payer and HTA requirements
\u2022 \u00A0 \u00A0Prior experience in the evaluation, development, and validation of PRO measures to support regulatory, payer, and HTA decision making
\u2022 \u00A0 \u00A0Experience supporting HTA submissions, value dossiers, and patient-relevant briefing books
\u2022 \u00A0 \u00A0Proven ability to influence and drive alignment across senior cross-functional stakeholders, including Value & Access, Commercial, Medical Affairs, Clinical Development & Regulatory Affairs
\u2022 \u00A0 \u00A0Ability to lead multiple complex initiatives and effectively prioritize in a dynamic, fast-paced environment
\u2022 \u00A0 \u00A0Recognized leader within the patient-reported outcomes field, with a strong professional network and external visibility
\u2022 \u00A0 \u00A0Experience engaging with external stakeholders, including HTA agencies, payers, health economists, clinical experts, and patient advocacy organizations
\u2022 \u00A0 \u00A0Rare disease experience preferred
\u2022 \u00A0 \u00A0Prior people leadership experience, including talent development preferred
Note: This description is not intended to be all-inclusive, or a limitation of the duties of the position. It is intended to describe the general nature of the job that may include other duties as assumed or assigned.
Equal Opportunity Employer/Veterans/Disabled
An Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability.
Ireland Safety Responsibility
Support the organisation\u2019s commitment to environmental protection, injury prevention, and continual improvement of EHS management systems. Actively contribute to a safe and environmentally responsible workplace by identifying hazards, reporting incidents and participating in EHS initiatives and training.
Careers Home Our Story Working Here Career Areas Locations { "@context": "http://schema.org", "@type": "JobPosting", "datePosted": "2026-08-18", "description": "
Who We Are
BioMarin is a leading rare disease biotechnology company focused on genetically defined conditions.
Guided by our purpose to develop medicines that make a profound impact on people\u2019s lives, our global teams have delivered a portfolio of therapies since our founding in 1997. Our revolutionary treatments for conditions like achondroplasia (the most common form of dwarfism), PKU (phenylketonuria), CLN2, a form of Batten disease, and a number of forms of MPS (mucopolysaccharidosis) offer new possibilities for patients and families who previously had few, if any, available options. More recently, with the close of the Amicus acquisition, our portfolio has expanded to include therapies for Fabry disease and Pompe disease, expanding our ability to reach more people living with rare genetic conditions.
Our success comes from our unwavering commitment to excellence, our deep understanding of patient needs, our scientific expertise, and our world-class manufacturing capabilities. At the heart of BioMarin is a dedicated team of the brightest minds in the industry working together to deliver innovative therapies to patients and families around the world.
About Commercial
Be part of the worldwide infrastructure that gets our drugs to underserved patients around the world. Our global sales force solidifies BioMarin\u2019s commercial presence in the United States and Europe and is rapidly growing in other regions, such as South America, EuMEA, and Asia-Pacific.
Who We Are
BioMarin is a leading rare disease biotechnology company focused on genetically defined conditions.
Guided by our purpose to develop medicines that make a profound impact on people\u2019s lives, our global teams have delivered a portfolio of therapies since our founding in 1997. Our revolutionary treatments for conditions like achondroplasia (the most common form of dwarfism), PKU (phenylketonuria), CLN2, a form of Batten disease, and a number of forms of MPS (mucopolysaccharidosis) offer new possibilities for patients and families who previously had few, if any, available options. More recently, with the close of the Amicus acquisition, our portfolio has expanded to include therapies for Fabry disease and Pompe disease, expanding our ability to reach more people living with rare genetic conditions.
Our success comes from our unwavering commitment to excellence, our deep understanding of patient needs, our scientific expertise, and our world-class manufacturing capabilities. At the heart of BioMarin is a dedicated team of the brightest minds in the industry working together to deliver innovative therapies to patients and families around the world.
\u00A0
Senior Director, Health Economics and Outcomes Research
Location: London ( hybrid role 2-3 days per week onsite)
Closing date: 31 August 2026
\u00A0
Summary
The Health Economics & Outcomes Research (HEOR) Senior Director leads asset-specific payer evidence strategies, including patient-relevant outcomes strategy, to generate differentiated evidence, strengthen the payer value proposition, and optimize access for BioMarin assets across all therapeutic areas of interest. s. The role is responsible for shaping patient-relevant outcomes requirements within the clinical programs, ensuring alignment with Regulatory, HTA and access needs. In partnership with internal cross-functional and external stakeholders, the Senior Director leads the design and execution of patient-relevant outcomes research initiatives.
The Sr. Director cultivates strong partnerships with cross-functional partners across Value & Access, Commercial, Medical Affairs, Clinical Development, Regulatory Affairs and Patient Advocacy, while engaging with external stakeholders including HTA agencies, payers and patient organizations. This role requires deep expertise in patient-relevant outcomes research and a strong understanding of market access, value and HTA frameworks.
The position reports to the ED, Head of the Global HEOR team, which sits within the Pricing Access Value & Evidence (PAVE) organization and has a direct report.
\u00A0
Description
\u2022 \u00A0 \u00A0Lead the development, execution and communication of payer evidence strategies aligned with brand and Value & Access priorities for early-stage pipeline assets
\u2022 \u00A0 \u00A0Collaborate closely with Value & Access, Commercial, Medical Affairs, Clinical Development & Regulatory Affairs & Patient Advocacy organizations
\u2022 \u00A0 \u00A0Drive organizational understanding of payer and HTA requirements related to patient-relevant outcomes and health utility measurement
\u2022 \u00A0 \u00A0Drive the strategic assessment for patient-relevant outcomes requirements for HTA and access to support differentiation and value demonstration
\u2022 \u00A0 \u00A0Ensure payer evidence requirements are incorporated into clinical development plans to enable optimal patient access
\u2022 \u00A0 \u00A0Lead the development of cross-functionally aligned, asset-specific patient-relevant outcomes strategies informed by disease conceptual models
\u2022 \u00A0 \u00A0Lead patient-relevant endpoint planning and provide oversight of implementation within clinical trials
\u2022 \u00A0 \u00A0Lead early Joint Clinical Assessment (JCA) strategy development, including assessment of access implications and trade-offs across markets
\u2022 \u00A0 \u00A0Assess payer evidence gaps and inform future integrated evidence planning for early-stage pipeline assets
\u2022 \u00A0 \u00A0Manage and partner with external partners in the execution of asset-level patient-relevant outcomes strategies, including PRO development and validation, health state valuation studies (time trade-off or standard gamble), and patient preference research, as appropriate
\u2022 \u00A0 \u00A0Lead scientific interactions with HTA agencies, particularly scientific advice (e.g., EU HTA JSC, NICE, CADTH), including preparation of briefing materials and evidence packages related to PRO endpoints, MCIDs, etc
\u2022 \u00A0 \u00A0Support scientific interactions with regulatory agencies and patient advocacy organizations
\u2022 \u00A0 \u00A0In partnership with the Integrated Evidence Teams (IET), lead the exploration, analysis and interpretation of patient-relevant outcomes data from clinical trials to generate insights, and strengthen value propositions for HTA, payer and other stakeholders
\u2022 \u00A0 \u00A0Shape strategic scientific communication plans, and lead presentation and publication of research in peer-reviewed journals
\u2022 \u00A0 \u00A0Assess business development opportunities against payer and HTA requirements to identify risks, evidence gaps, and access considerations
\u00A0
Education & Experience
\u2022 \u00A0 \u00A012+ years of Pharma Industry experience with 7+ years of experience in HEOR roles in pharmaceutical companies or consulting, and at least 5 years of direct experience with patient-relevant outcomes research
\u2022 \u00A0 \u00A0Advanced degree in health economics, outcomes research, epidemiology, public health, health services research, pharmacy, or a related scientific discipline
\u2022 \u00A0 \u00A0Deep understanding of market access, value and global HTA frameworks
\u2022 \u00A0 \u00A0Demonstrated experience developing and executing patient-relevant outcomes strategies to meet payer and HTA requirements
\u2022 \u00A0 \u00A0Prior experience in the evaluation, development, and validation of PRO measures to support regulatory, payer, and HTA decision making
\u2022 \u00A0 \u00A0Experience supporting HTA submissions, value dossiers, and patient-relevant briefing books
\u2022 \u00A0 \u00A0Proven ability to influence and drive alignment across senior cross-functional stakeholders, including Value & Access, Commercial, Medical Affairs, Clinical Development & Regulatory Affairs
\u2022 \u00A0 \u00A0Ability to lead multiple complex initiatives and effectively prioritize in a dynamic, fast-paced environment
\u2022 \u00A0 \u00A0Recognized leader within the patient-reported outcomes field, with a strong professional network and external visibility
\u2022 \u00A0 \u00A0Experience engaging with external stakeholders, including HTA agencies, payers, health economists, clinical experts, and patient advocacy organizations
\u2022 \u00A0 \u00A0Rare disease experience preferred
\u2022 \u00A0 \u00A0Prior people leadership experience, including talent development preferred
Note: This description is not intended to be all-inclusive, or a limitation of the duties of the position. It is intended to describe the general nature of the job that may include other duties as assumed or assigned.
Equal Opportunity Employer/Veterans/Disabled
An Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability.
Ireland Safety Responsibility
Support the organisation\u2019s commitment to environmental protection, injury prevention, and continual improvement of EHS management systems. Actively contribute to a safe and environmentally responsible workplace by identifying hazards, reporting incidents and participating in EHS initiatives and training.
Careers Home Our Story Working Here Career Areas Locations { "@context": "http://schema.org", "@type": "JobPosting", "datePosted": "2026-08-18", "description": "
Who We Are
BioMarin is a leading rare disease biotechnology company focused on genetically defined conditions.
Guided by our purpose to develop medicines that make a profound impact on people\u2019s lives, our global teams have delivered a portfolio of therapies since our founding in 1997. Our revolutionary treatments for conditions like achondroplasia (the most common form of dwarfism), PKU (phenylketonuria), CLN2, a form of Batten disease, and a number of forms of MPS (mucopolysaccharidosis) offer new possibilities for patients and families who previously had few, if any, available options. More recently, with the close of the Amicus acquisition, our portfolio has expanded to include therapies for Fabry disease and Pompe disease, expanding our ability to reach more people living with rare genetic conditions.
Our success comes from our unwavering commitment to excellence, our deep understanding of patient needs, our scientific expertise, and our world-class manufacturing capabilities. At the heart of BioMarin is a dedicated team of the brightest minds in the industry working together to deliver innovative therapies to patients and families around the world.
About Commercial
Be part of the worldwide infrastructure that gets our drugs to underserved patients around the world. Our global sales force solidifies BioMarin\u2019s commercial presence in the United States and Europe and is rapidly growing in other regions, such as South America, EuMEA, and Asia-Pacific.
Who We Are
BioMarin is a leading rare disease biotechnology company focused on genetically defined conditions.
Guided by our purpose to develop medicines that make a profound impact on people\u2019s lives, our global teams have delivered a portfolio of therapies since our founding in 1997. Our revolutionary treatments for conditions like achondroplasia (the most common form of dwarfism), PKU (phenylketonuria), CLN2, a form of Batten disease, and a number of forms of MPS (mucopolysaccharidosis) offer new possibilities for patients and families who previously had few, if any, available options. More recently, with the close of the Amicus acquisition, our portfolio has expanded to include therapies for Fabry disease and Pompe disease, expanding our ability to reach more people living with rare genetic conditions.
Our success comes from our unwavering commitment to excellence, our deep understanding of patient needs, our scientific expertise, and our world-class manufacturing capabilities. At the heart of BioMarin is a dedicated team of the brightest minds in the industry working together to deliver innovative therapies to patients and families around the world.
\u00A0
Senior Director, Health Economics and Outcomes Research
Location: London ( hybrid role 2-3 days per week onsite)
Closing date: 31 August 2026
\u00A0
Summary
The Health Economics & Outcomes Research (HEOR) Senior Director leads asset-specific payer evidence strategies, including patient-relevant outcomes strategy, to generate differentiated evidence, strengthen the payer value proposition, and optimize access for BioMarin assets across all therapeutic areas of interest. s. The role is responsible for shaping patient-relevant outcomes requirements within the clinical programs, ensuring alignment with Regulatory, HTA and access needs. In partnership with internal cross-functional and external stakeholders, the Senior Director leads the design and execution of patient-relevant outcomes research initiatives.
The Sr. Director cultivates strong partnerships with cross-functional partners across Value & Access, Commercial, Medical Affairs, Clinical Development, Regulatory Affairs and Patient Advocacy, while engaging with external stakeholders including HTA agencies, payers and patient organizations. This role requires deep expertise in patient-relevant outcomes research and a strong understanding of market access, value and HTA frameworks.
The position reports to the ED, Head of the Global HEOR team, which sits within the Pricing Access Value & Evidence (PAVE) organization and has a direct report.
\u00A0
Description
\u2022 \u00A0 \u00A0Lead the development, execution and communication of payer evidence strategies aligned with brand and Value & Access priorities for early-stage pipeline assets
\u2022 \u00A0 \u00A0Collaborate closely with Value & Access, Commercial, Medical Affairs, Clinical Development & Regulatory Affairs & Patient Advocacy organizations
\u2022 \u00A0 \u00A0Drive organizational understanding of payer and HTA requirements related to patient-relevant outcomes and health utility measurement
\u2022 \u00A0 \u00A0Drive the strategic assessment for patient-relevant outcomes requirements for HTA and access to support differentiation and value demonstration
\u2022 \u00A0 \u00A0Ensure payer evidence requirements are incorporated into clinical development plans to enable optimal patient access
\u2022 \u00A0 \u00A0Lead the development of cross-functionally aligned, asset-specific patient-relevant outcomes strategies informed by disease conceptual models
\u2022 \u00A0 \u00A0Lead patient-relevant endpoint planning and provide oversight of implementation within clinical trials
\u2022 \u00A0 \u00A0Lead early Joint Clinical Assessment (JCA) strategy development, including assessment of access implications and trade-offs across markets
\u2022 \u00A0 \u00A0Assess payer evidence gaps and inform future integrated evidence planning for early-stage pipeline assets
\u2022 \u00A0 \u00A0Manage and partner with external partners in the execution of asset-level patient-relevant outcomes strategies, including PRO development and validation, health state valuation studies (time trade-off or standard gamble), and patient preference research, as appropriate
\u2022 \u00A0 \u00A0Lead scientific interactions with HTA agencies, particularly scientific advice (e.g., EU HTA JSC, NICE, CADTH), including preparation of briefing materials and evidence packages related to PRO endpoints, MCIDs, etc
\u2022 \u00A0 \u00A0Support scientific interactions with regulatory agencies and patient advocacy organizations
\u2022 \u00A0 \u00A0In partnership with the Integrated Evidence Teams (IET), lead the exploration, analysis and interpretation of patient-relevant outcomes data from clinical trials to generate insights, and strengthen value propositions for HTA, payer and other stakeholders
\u2022 \u00A0 \u00A0Shape strategic scientific communication plans, and lead presentation and publication of research in peer-reviewed journals
\u2022 \u00A0 \u00A0Assess business development opportunities against payer and HTA requirements to identify risks, evidence gaps, and access considerations
\u00A0
Education & Experience
\u2022 \u00A0 \u00A012+ years of Pharma Industry experience with 7+ years of experience in HEOR roles in pharmaceutical companies or consulting, and at least 5 years of direct experience with patient-relevant outcomes research
\u2022 \u00A0 \u00A0Advanced degree in health economics, outcomes research, epidemiology, public health, health services research, pharmacy, or a related scientific discipline
\u2022 \u00A0 \u00A0Deep understanding of market access, value and global HTA frameworks
\u2022 \u00A0 \u00A0Demonstrated experience developing and executing patient-relevant outcomes strategies to meet payer and HTA requirements
\u2022 \u00A0 \u00A0Prior experience in the evaluation, development, and validation of PRO measures to support regulatory, payer, and HTA decision making
\u2022 \u00A0 \u00A0Experience supporting HTA submissions, value dossiers, and patient-relevant briefing books
\u2022 \u00A0 \u00A0Proven ability to influence and drive alignment across senior cross-functional stakeholders, including Value & Access, Commercial, Medical Affairs, Clinical Development & Regulatory Affairs
\u2022 \u00A0 \u00A0Ability to lead multiple complex initiatives and effectively prioritize in a dynamic, fast-paced environment
\u2022 \u00A0 \u00A0Recognized leader within the patient-reported outcomes field, with a strong professional network and external visibility
\u2022 \u00A0 \u00A0Experience engaging with external stakeholders, including HTA agencies, payers, health economists, clinical experts, and patient advocacy organizations
\u2022 \u00A0 \u00A0Rare disease experience preferred
\u2022 \u00A0 \u00A0Prior people leadership experience, including talent development preferred
Note: This description is not intended to be all-inclusive, or a limitation of the duties of the position. It is intended to describe the general nature of the job that may include other duties as assumed or assigned.
Equal Opportunity Employer/Veterans/Disabled
An Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability.
Ireland Safety Responsibility
Support the organisation\u2019s commitment to environmental protection, injury prevention, and continual improvement of EHS management systems. Actively contribute to a safe and environmentally responsible workplace by identifying hazards, reporting incidents and participating in EHS initiatives and training.
Careers Home Our Story Working Here Career Areas Locations
Careers Home Our Story Working Here Career Areas Locations
Careers Home
Careers Home
Our Story
Our Story
Working Here
Working Here
Career Areas
Career Areas
Locations
Locations
{ "@context": "http://schema.org", "@type": "JobPosting", "datePosted": "2026-08-18", "description": "
Who We Are
BioMarin is a leading rare disease biotechnology company focused on genetically defined conditions.
Guided by our purpose to develop medicines that make a profound impact on people\u2019s lives, our global teams have delivered a portfolio of therapies since our founding in 1997. Our revolutionary treatments for conditions like achondroplasia (the most common form of dwarfism), PKU (phenylketonuria), CLN2, a form of Batten disease, and a number of forms of MPS (mucopolysaccharidosis) offer new possibilities for patients and families who previously had few, if any, available options. More recently, with the close of the Amicus acquisition, our portfolio has expanded to include therapies for Fabry disease and Pompe disease, expanding our ability to reach more people living with rare genetic conditions.
Our success comes from our unwavering commitment to excellence, our deep understanding of patient needs, our scientific expertise, and our world-class manufacturing capabilities. At the heart of BioMarin is a dedicated team of the brightest minds in the industry working together to deliver innovative therapies to patients and families around the world.
About Commercial
Be part of the worldwide infrastructure that gets our drugs to underserved patients around the world. Our global sales force solidifies BioMarin\u2019s commercial presence in the United States and Europe and is rapidly growing in other regions, such as South America, EuMEA, and Asia-Pacific.
Who We Are
BioMarin is a leading rare disease biotechnology company focused on genetically defined conditions.
Guided by our purpose to develop medicines that make a profound impact on people\u2019s lives, our global teams have delivered a portfolio of therapies since our founding in 1997. Our revolutionary treatments for conditions like achondroplasia (the most common form of dwarfism), PKU (phenylketonuria), CLN2, a form of Batten disease, and a number of forms of MPS (mucopolysaccharidosis) offer new possibilities for patients and families who previously had few, if any, available options. More recently, with the close of the Amicus acquisition, our portfolio has expanded to include therapies for Fabry disease and Pompe disease, expanding our ability to reach more people living with rare genetic conditions.
Our success comes from our unwavering commitment to excellence, our deep understanding of patient needs, our scientific expertise, and our world-class manufacturing capabilities. At the heart of BioMarin is a dedicated team of the brightest minds in the industry working together to deliver innovative therapies to patients and families around the world.
\u00A0
Senior Director, Health Economics and Outcomes Research
Location: London ( hybrid role 2-3 days per week onsite)
Closing date: 31 August 2026
\u00A0
Summary
The Health Economics & Outcomes Research (HEOR) Senior Director leads asset-specific payer evidence strategies, including patient-relevant outcomes strategy, to generate differentiated evidence, strengthen the payer value proposition, and optimize access for BioMarin assets across all therapeutic areas of interest. s. The role is responsible for shaping patient-relevant outcomes requirements within the clinical programs, ensuring alignment with Regulatory, HTA and access needs. In partnership with internal cross-functional and external stakeholders, the Senior Director leads the design and execution of patient-relevant outcomes research initiatives.
The Sr. Director cultivates strong partnerships with cross-functional partners across Value & Access, Commercial, Medical Affairs, Clinical Development, Regulatory Affairs and Patient Advocacy, while engaging with external stakeholders including HTA agencies, payers and patient organizations. This role requires deep expertise in patient-relevant outcomes research and a strong understanding of market access, value and HTA frameworks.
The position reports to the ED, Head of the Global HEOR team, which sits within the Pricing Access Value & Evidence (PAVE) organization and has a direct report.
\u00A0
Description
\u2022 \u00A0 \u00A0Lead the development, execution and communication of payer evidence strategies aligned with brand and Value & Access priorities for early-stage pipeline assets
\u2022 \u00A0 \u00A0Collaborate closely with Value & Access, Commercial, Medical Affairs, Clinical Development & Regulatory Affairs & Patient Advocacy organizations
\u2022 \u00A0 \u00A0Drive organizational understanding of payer and HTA requirements related to patient-relevant outcomes and health utility measurement
\u2022 \u00A0 \u00A0Drive the strategic assessment for patient-relevant outcomes requirements for HTA and access to support differentiation and value demonstration
\u2022 \u00A0 \u00A0Ensure payer evidence requirements are incorporated into clinical development plans to enable optimal patient access
\u2022 \u00A0 \u00A0Lead the development of cross-functionally aligned, asset-specific patient-relevant outcomes strategies informed by disease conceptual models
\u2022 \u00A0 \u00A0Lead patient-relevant endpoint planning and provide oversight of implementation within clinical trials
\u2022 \u00A0 \u00A0Lead early Joint Clinical Assessment (JCA) strategy development, including assessment of access implications and trade-offs across markets
\u2022 \u00A0 \u00A0Assess payer evidence gaps and inform future integrated evidence planning for early-stage pipeline assets
\u2022 \u00A0 \u00A0Manage and partner with external partners in the execution of asset-level patient-relevant outcomes strategies, including PRO development and validation, health state valuation studies (time trade-off or standard gamble), and patient preference research, as appropriate
\u2022 \u00A0 \u00A0Lead scientific interactions with HTA agencies, particularly scientific advice (e.g., EU HTA JSC, NICE, CADTH), including preparation of briefing materials and evidence packages related to PRO endpoints, MCIDs, etc
\u2022 \u00A0 \u00A0Support scientific interactions with regulatory agencies and patient advocacy organizations
\u2022 \u00A0 \u00A0In partnership with the Integrated Evidence Teams (IET), lead the exploration, analysis and interpretation of patient-relevant outcomes data from clinical trials to generate insights, and strengthen value propositions for HTA, payer and other stakeholders
\u2022 \u00A0 \u00A0Shape strategic scientific communication plans, and lead presentation and publication of research in peer-reviewed journals
\u2022 \u00A0 \u00A0Assess business development opportunities against payer and HTA requirements to identify risks, evidence gaps, and access considerations
\u00A0
Education & Experience
\u2022 \u00A0 \u00A012+ years of Pharma Industry experience with 7+ years of experience in HEOR roles in pharmaceutical companies or consulting, and at least 5 years of direct experience with patient-relevant outcomes research
\u2022 \u00A0 \u00A0Advanced degree in health economics, outcomes research, epidemiology, public health, health services research, pharmacy, or a related scientific discipline
\u2022 \u00A0 \u00A0Deep understanding of market access, value and global HTA frameworks
\u2022 \u00A0 \u00A0Demonstrated experience developing and executing patient-relevant outcomes strategies to meet payer and HTA requirements
\u2022 \u00A0 \u00A0Prior experience in the evaluation, development, and validation of PRO measures to support regulatory, payer, and HTA decision making
\u2022 \u00A0 \u00A0Experience supporting HTA submissions, value dossiers, and patient-relevant briefing books
\u2022 \u00A0 \u00A0Proven ability to influence and drive alignment across senior cross-functional stakeholders, including Value & Access, Commercial, Medical Affairs, Clinical Development & Regulatory Affairs
\u2022 \u00A0 \u00A0Ability to lead multiple complex initiatives and effectively prioritize in a dynamic, fast-paced environment
\u2022 \u00A0 \u00A0Recognized leader within the patient-reported outcomes field, with a strong professional network and external visibility
\u2022 \u00A0 \u00A0Experience engaging with external stakeholders, including HTA agencies, payers, health economists, clinical experts, and patient advocacy organizations
\u2022 \u00A0 \u00A0Rare disease experience preferred
\u2022 \u00A0 \u00A0Prior people leadership experience, including talent development preferred
Note: This description is not intended to be all-inclusive, or a limitation of the duties of the position. It is intended to describe the general nature of the job that may include other duties as assumed or assigned.
Equal Opportunity Employer/Veterans/Disabled
An Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability.
Ireland Safety Responsibility
Support the organisation\u2019s commitment to environmental protection, injury prevention, and continual improvement of EHS management systems. Actively contribute to a safe and environmentally responsible workplace by identifying hazards, reporting incidents and participating in EHS initiatives and training.
Senior Director, Health Economics & Outcomes Research (HEOR)
Location: London, United Kingdom Category: Commercial Operations
Location: London, United Kingdom
Location:
Category: Commercial Operations
Category:
Similar jobs
London, United KingdomSenior
posted 4 days ago
Senior
posted 6 days ago